(4’-氟联苯-4-基)甲胺 | 776291-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4’-氟联苯-4-基)甲胺
• 英文名称: (4'-fluoro-[1,1'-biphenyl]-4-yl)methanamine
• 英文别名: (4'-fluorobiphenyl-4-yl)methanamine；(4'-fluorobiphenyl-4-yl)methylamine；(4'-fluoro-4-biphenyl)methylamine；4-(4-fluorophenyl)-benzylamine；4-(4-fluorophenyl)benzylamine；4'-FLUORO-BIPHENYL-4-METHANamine；[4-(4-fluorophenyl)phenyl]methanamine
• CAS: 776291-03-3
• 化学式: C₁₃H₁₂FN
• 分子量: 201.243
• InChiKey: BGOOSUGWQICZRA-UHFFFAOYSA-N

物化性质

• 熔点：
  270-272 °C
• 沸点：
  322.9±30.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4’-氟联苯-4-基)甲胺 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 以4.99 g的产率得到C-(4-氟-联苯-4-基)-甲胺盐酸盐
  参考文献：
  名称：

  (Biphenyl-4-yl)methylammonium Chlorides: Potent Anticonvulsants That Modulate Na⁺ Currents

  摘要：

  We have reported that compounds containing a biaryl linked unit (Ar-X-Ar') modulated Na+ currents by promoting slow inactivation and fast inactivation processes and by inducing frequency (use)-dependent inhibition of Na+ currents. These electrophysiological properties have been drugs. In this study, we demonstrate that the readily accessible associated with the mode of action of several antiepileptic (biphenyl-4-yl)methylammonium chlorides (compound class B) exhibited a broad range of anticonvulsant activities in animal models, and in the maximal electroshock seizure test the activity of (3'-trifluoromethoxybiphenyl-4-yl)methylammonium chloride (8) exceeded that of phenobarbital and phenytoin upon oral administration to rats. Electrophysiological studies of 8 using mouse catecholamine A-differentiated cells and rat embryonic cortical neurons confirmed that 8 promoted slow and fast inactivation in both cell types but did not affect the frequency (use)-dependent block of Na+ currents.

  DOI：

  10.1021/jm4007092
• 作为产物：
  描述：

  4-(4-氟苯基)苯甲醛 在 sodium tetrahydroborate 、 邻苯二甲酸亚胺 、 三苯基膦 、 偶氮二甲酸二乙酯 、 肼 作用下， 以 乙醇 、 四氢呋喃 为溶剂， 生成 (4’-氟联苯-4-基)甲胺
  参考文献：
  名称：

  Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidones

  摘要：

  A series of 1-(biphenylmethylamidoalkyl)-pyrimidones has been designed as nanomolar inhibitors of recombinant lipoprotein-associated phospholipase A(2) with high potency in whole human plasma. 5-(Pyrazolylmethyl) derivative 16 and 5-(methoxypyrimidinylmethyl) derivative 27 demonstrated excellent pharmacodynamic profiles which correlated well with their pharmacokinetic effects. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00678-3

文献信息

• Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators
  作者：Iain R. Greig、Gemma L. Baillie、Mostafa Abdelrahman、Laurent Trembleau、Ruth A. Ross

  DOI：10.1016/j.bmcl.2016.08.018

  日期：2016.9

  CB1-mediated effects. Thus, a greater range of molecular tools are required to allow definitive elucidation of the effects of CB1 allosteric modulation. In this study, we show a novel series of indole sulfonamides. Compounds 5e and 6c (ABD1075) had potencies of 4 and 3nM respectively, and showed good oral exposure and CNS penetration, making them highly versatile tools for investigating the therapeutic

  现有的CB1阴性变构调节剂（NAM）属于结构类别的有限范围。尽管具有CB1 NAM的理论潜力，但已发表的体内研究通常不能证明预期的与治疗相关的CB1介导的作用。因此，需要更大范围的分子工具才能明确阐明CB1变构调节作用。在这项研究中，我们显示了一系列新颖的吲哚磺酰胺。化合物5e和6c（ABD1075）的效力分别为4和3nM，并显示出良好的口服暴露和CNS渗透性，使其成为研究大麻素系统的变构调节作用的潜在治疗工具。
• Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
  申请人：——

  公开号：US20020032238A1

  公开（公告）日：2002-03-14

  The present invention relates to substituted piperazine derivatives of general formula 1 wherein R 1 to R 7 are defined herein, the isomers and salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.

  本发明涉及一般式1的取代哌嗪衍生物，其中R1至R7在此处定义，其异构体和盐，特别是其生理上可接受的盐，这些盐是微粒体三酰甘油转移蛋白（MTP）的有价值的抑制剂，含有这些化合物的药物以及它们的用途，以及其制备。
• Novel series of substituted biphenylmethyl urea derivatives as MCH-R1 antagonists for the treatment of obesity
  作者：Silvia Galiano、Javier Ceras、Nuria Cirauqui、Silvia Pérez、Laura Juanenea、Gildardo Rivera、Ignacio Aldana、Antonio Monge

  DOI：10.1016/j.bmc.2007.02.049

  日期：2007.6.1

  MCH-R1 antagonists based on a substituted biphenylmethyl urea core. SAR was explored, suggesting that optimal binding with the receptor was achieved when the biphenylmethyl group and the linker were substituted on the same nitrogen of the urea moiety. Compound 1-(3'-cyano-4-biphenylmethyl)-3-(2-hydroxy-1,1-dimethylethyl)-1-2-[1-(4-methylbe nzyl)-4-piperidinyl]ethyl}urea 2t showed the best antagonist

  我们已经基于取代的联苯甲基尿素核心设计并合成了两个新颖的MCH-R1拮抗剂系列。探索了SAR，表明当联苯甲基和连接基被尿素部分的相同氮取代时，与受体的最佳结合得以实现。化合物1-（3'-氰基-4-联苯甲基）-3-（2-羟基-1,1-二甲基乙基）-1- 2- [1-（4-甲基苄基）-4-哌啶基]乙基}脲2t以43 nM K（i）显示出对MCH-R1的最佳拮抗剂结合活性。
• Probing structural requirements for human topoisomerase I inhibition by a novel N1-Biphenyl fluoroquinolone
  作者：Justine L. Delgado、Sarah R.C. Lentz、Chaitanya A. Kulkarni、Pratik R. Chheda、Hailey A. Held、Hiroshi Hiasa、Robert J. Kerns

  DOI：10.1016/j.ejmech.2019.03.040

  日期：2019.6

  synthesized and evaluated to understand structural requirements of the C-3 carboxylic acid, C-6 fluorine, C-7 aminomethylpyrrolidine, C-8 methoxy, and the N-1 biphenyl functional groups for hTopoI inhibition. Characterization of each analog for inhibition of hTopoI catalytic inhibition reveals critical insight into structural requirements of these novel quinolones for activity. Additionally, results of DNA binding

  发现被N-1联苯基和萘基取代的氟喹诺酮类化合物可作为人拓扑异构酶I和II的催化抑制剂，并在体内具有抗增殖活性。这些新颖的喹诺酮类抑制人拓扑异构酶I催化活性的结构要求尚未探索。在这项工作中，设计，合成和评估N-1联苯氟喹诺酮的新型衍生物，以了解C-3羧酸，C-6氟，C-7氨基甲基吡咯烷，C-8甲氧基和N-1的结构要求联苯官能团可抑制hTopoI。每种抑制hTopoI催化抑制的类似物的表征揭示了对这些新型喹诺酮对活性的结构要求的关键见识。此外，DNA结合和模型研究的结果表明，N-1联苯氟喹诺酮类药物插入具有N-1联苯官能团而不是喹诺酮核心的DNA碱基对之间，并且这种DNA嵌入方式有助于抑制hTopoI。结构。本文介绍的结果支持N-1联苯氟喹诺酮类似物作为一类新型的抗癌药的进一步开发和评估，该类抗癌药通过催化hTopoI发挥作用。
• [EN] PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE<br/>[FR] COMPOSÉS PYRIMIDINE QUI INHIBENT LA KINASE DU LYMPHOME ANAPLASIQUE
  申请人：AMGEN INC

  公开号：WO2011143033A1

  公开（公告）日：2011-11-17

  Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  Formula I的化合物是一种有用的间变性淋巴瘤激酶抑制剂。Formula I的化合物具有以下结构：变量的定义在此提供。